<DOC>
	<DOCNO>NCT01216267</DOCNO>
	<brief_summary>The goal study compare several method measurement Chromogranin A ability serve marker disease activity patient neuroendocrine tumor . Further , subgroup , determine take proton pump inhibitor affect Chromogranin A level .</brief_summary>
	<brief_title>Evaluation Methods Determination Chromogranin A Routine Blood Samples</brief_title>
	<detailed_description>Patient group : patient neuroendocrine tumor ( active inactive ) Healthy volunteer</detailed_description>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>Patients : neuroendocrine disease age 18 70 year prostate cancer kidney failure ( estimate GF &lt; 30 mL/Min ) heart failure chronic atrophic gastritis pregnancy Healthy subject : healthy age 18 70 year take chronic medication ( except OCP ) prostate cancer kidney failure ( estimate GFR &lt; 30 mL/min ) heart failure pheochromocytoma islet cell tumor medullary thyroid cancer essential hypertension neurofibromatosis use proton pump inhibitor chronic atrophic gastritis pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>chromogranin A</keyword>
	<keyword>neuroendocrine</keyword>
	<keyword>carcinoid</keyword>
	<keyword>Proton Pump Inhibitor</keyword>
</DOC>